Loading stock data…
$14.37-0.13 (-0.90%)
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
Iovance Biotherapeutics, Inc. in the Healthcare sector is trading at $14.37 with a market capitalization of $3.9B. Wall Street consensus targets $14.40 (10 analysts), implying a +0.2% move over the next 12 months. The stock is currently near its 52-week high of $15.30, remaining 177.4% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $99.31M↑ | $71.43M↓ | $86.77M↑ | $67.45M↑ | $59.95M |
| Gross Profit | $55.72M↑ | $28.93M↓ | $43.66M↑ | $28.98M↑ | $11.07M |
| Operating Income | -$51.91M↑ | -$81.04M↓ | -$73.46M↑ | -$89.76M↑ | -$113.77M |
| Net Income | -$47.31M↑ | -$79.05M↓ | -$71.90M↑ | -$91.25M↑ | -$111.66M |
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the Unite...